[go: up one dir, main page]

Hinderer et al., 2020 - Google Patents

Adeno‐associated virus serotype 1‐based gene therapy for FTD caused by GRN mutations

Hinderer et al., 2020

View PDF @Full View
Document ID
17765451688409343843
Author
Hinderer C
Miller R
Dyer C
Johansson J
Bell P
Buza E
Wilson J
Publication year
Publication venue
Annals of Clinical and Translational Neurology

External Links

Snippet

Objective Dominant loss‐of‐function mutations in the gene encoding the lysosomal protein, progranulin, cause 5‐10% of frontotemporal dementia cases. As progranulin undergoes secretion and endocytosis, a small number of progranulin‐expressing cells can potentially …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
Hinderer et al. Adeno‐associated virus serotype 1‐based gene therapy for FTD caused by GRN mutations
Wang et al. Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14
Thomsen et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Gautier et al. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A
Coryell et al. Acid-sensing ion channel-1a in the amygdala, a novel therapeutic target in depression-related behavior
Wegmann et al. Persistent repression of tau in the brain using engineered zinc finger protein transcription factors
Decressac et al. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson’s disease
Miquel-Rio et al. Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy
Bradbury et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease)
van Loo et al. Inhibition of transcription factor NF-κB in the central nervous system ameliorates autoimmune encephalomyelitis in mice
Glascock et al. Decreasing disease severity in symptomatic, Smn−/−; SMN2+/+, spinal muscular atrophy mice following scAAV9-SMN delivery
Paul et al. Trophic factors for Parkinson's disease: where are we and where do we go from here?
Johnston et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys
Nagahara et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease
Sevin et al. Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy
Samaranch et al. Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type A
Johnson et al. AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-batten disease
Bucher et al. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease
Zeier et al. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome
Rompuy et al. Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration
DeRosa et al. MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV
Sorrentino et al. A comprehensive map of CNS transduction by eight recombinant adeno-associated virus serotypes upon cerebrospinal fluid administration in pigs
Olfat et al. Increased physiological GDNF levels have no effect on dopamine neuron protection and restoration in a proteasome inhibition mouse model of Parkinson’s disease
Gray et al. An improved adeno-associated virus vector for neurological correction of the mouse model of mucopolysaccharidosis IIIA
Hunanyan et al. Adeno-associated virus-mediated gene therapy in the Mashlool, Atp1a3Mashl/+, mouse model of alternating hemiplegia of childhood